WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 526982
CAS#: 135525-78-9
Description: L-697661 is a reverse transcriptase inhibitor potentially for the treatment of HIV infection.
MedKoo Cat#: 526982
Name: L-697661
CAS#: 135525-78-9
Chemical Formula: C16H15Cl2N3O2
Exact Mass: 351.0541
Molecular Weight: 352.21
Elemental Analysis: C, 54.56; H, 4.29; Cl, 20.13; N, 11.93; O, 9.08
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: L-697661; L 697661; L697661; L-697,661; L 697,661; L697,661.
IUPAC/Chemical Name: 3-(((4,7-dichlorobenzo[d]oxazol-2-yl)methyl)amino)-5-ethyl-6-methylpyridin-2(1H)-one
InChi Key: WHFRDXVXYMGAJD-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H15Cl2N3O2/c1-3-9-6-12(16(22)20-8(9)2)19-7-13-21-14-10(17)4-5-11(18)15(14)23-13/h4-6,19H,3,7H2,1-2H3,(H,20,22)
SMILES Code: O=C1C(NCC2=NC3=C(Cl)C=CC(Cl)=C3O2)=CC(CC)=C(C)N1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 352.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Perrin L, Rakik A, Yerly S, Baumberger C, Kinloch-de Loës S, Pechère M, Hirschel B. Combined therapy with zidovudine and L-697,661 in primary HIV infection. AIDS. 1996 Sep;10(11):1233-7. PubMed PMID: 8883585.
2: Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari F, Collier A, Kahn J. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 1;12(4):363-70. PubMed PMID: 8673545.
3: Kilby JM, Saag MS. Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine. Adv Exp Med Biol. 1996;394:291-8. Review. PubMed PMID: 8815693.
4: Staszewski S, Massari FE, Kober A, Göhler R, Durr S, Anderson KW, Schneider CL, Waterbury JA, Bakshi KK, Taylor VI, et al. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis. 1995 May;171(5):1159-65. PubMed PMID: 7538547.
5: Fan N, Evans DB, Rank KB, Thomas RC, Tarpley WG, Sharma SK. Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. FEBS Lett. 1995 Feb 13;359(2-3):233-8. PubMed PMID: 7532595.
6: Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med. 1993 Oct 7;329(15):1065-72. PubMed PMID: 7690462.
7: Davey RT Jr, Dewar RL, Reed GF, Vasudevachari MB, Polis MA, Kovacs JA, Falloon J, Walker RE, Masur H, Haneiwich SE, et al. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5608-12. PubMed PMID: 8516307; PubMed Central PMCID: PMC46770.
8: Harris PJ. Possible toxicity associated with L-697,661 administration in a patient with AIDS. AIDS. 1992 Jun;6(6):597-9. PubMed PMID: 1382453.
